NCT02558894 - Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 16, 2015

Primary Completion Date

June 15, 2017

Study Completion Date

June 15, 2017

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

MEDI4736 monotherapy

MEDI4736 via IV infusion.

DRUG

tremelimumab+MEDI4736

tremelimumab+MEDI4736 via IV infusion.

Trial Locations (21)

10065

Research Site, New York

28034

Research Site, Madrid

33612

Research Site, Tampa

72076

Research Site, Tübingen

81377

Research Site, München

88045

Research Site, Friedrichshafen

V5Z 4E6

Research Site, Vancouver

L1G 2B9

Research Site, Oshawa

K1H 8L6

Research Site, Ottawa

M4N 3M5

Research Site, Toronto

M5G 2M9

Research Site, Toronto

H4A 3T2

Research Site, Montreal

1105 AZ

Research Site, Amsterdam

9713 GZ

Research Site, Groningen

6525 GA

Research Site, Nijmegen

463-707

Research Site, Seongnam-si

03080

Research Site, Seoul

03722

Research Site, Seoul

06591

Research Site, Seoul

135-710

Research Site, Seoul

08035

Research Site, Barcelona